FR2790955B1 - Utilisation d'oligonucleotides stabilises comme principe actif antitumoral - Google Patents

Utilisation d'oligonucleotides stabilises comme principe actif antitumoral

Info

Publication number
FR2790955B1
FR2790955B1 FR9903433A FR9903433A FR2790955B1 FR 2790955 B1 FR2790955 B1 FR 2790955B1 FR 9903433 A FR9903433 A FR 9903433A FR 9903433 A FR9903433 A FR 9903433A FR 2790955 B1 FR2790955 B1 FR 2790955B1
Authority
FR
France
Prior art keywords
active ingredient
stabilized oligonucleotides
tumor active
oligonucleotides
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9903433A
Other languages
English (en)
French (fr)
Other versions
FR2790955A1 (fr
Inventor
Antoine Carpentier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9903433A priority Critical patent/FR2790955B1/fr
Application filed by Assistance Publique Hopitaux de Paris APHP filed Critical Assistance Publique Hopitaux de Paris APHP
Priority to JP2000606246A priority patent/JP2002539265A/ja
Priority to PT00910993T priority patent/PT1162982E/pt
Priority to AU33006/00A priority patent/AU3300600A/en
Priority to US09/937,057 priority patent/US7700569B1/en
Priority to DK00910993T priority patent/DK1162982T3/da
Priority to DE60018050T priority patent/DE60018050T2/de
Priority to CA002371990A priority patent/CA2371990A1/fr
Priority to AT00910993T priority patent/ATE288759T1/de
Priority to EP00910993A priority patent/EP1162982B9/fr
Priority to ES00910993T priority patent/ES2235839T3/es
Priority to PCT/FR2000/000676 priority patent/WO2000056342A2/fr
Publication of FR2790955A1 publication Critical patent/FR2790955A1/fr
Priority to US09/967,881 priority patent/US7108844B2/en
Application granted granted Critical
Publication of FR2790955B1 publication Critical patent/FR2790955B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
FR9903433A 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral Expired - Fee Related FR2790955B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR9903433A FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
ES00910993T ES2235839T3 (es) 1999-03-19 2000-03-17 Uso de oligonucleotidos estabilizados para la preparacion de un medicamento de accion antitumoral.
AU33006/00A AU3300600A (en) 1999-03-19 2000-03-17 Use of stabilised oligonucleotides for preparing a medicine with antitumour activity
US09/937,057 US7700569B1 (en) 1999-03-19 2000-03-17 Use of stabilised oligonucleotides for preparing a medicine with antitumor activity
DK00910993T DK1162982T3 (da) 1999-03-19 2000-03-17 Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
DE60018050T DE60018050T2 (de) 1999-03-19 2000-03-17 VERWENDUNG VON STABILISIERTEn OLIGONUCLEOTIDEn ZUR HERSTELLUNG VON ANTITUMORALen ARZNEIMITTELn
JP2000606246A JP2002539265A (ja) 1999-03-19 2000-03-17 抗腫瘍活性を有する薬剤を製造するための安定化オリゴヌクレオチドの使用
AT00910993T ATE288759T1 (de) 1999-03-19 2000-03-17 Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimitteln
EP00910993A EP1162982B9 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale
PT00910993T PT1162982E (pt) 1999-03-19 2000-03-17 Utilizacao de oligonucleotidos estabilizados pata a preparacao de um meicamento com accao anti-tumor
PCT/FR2000/000676 WO2000056342A2 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale
CA002371990A CA2371990A1 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale
US09/967,881 US7108844B2 (en) 1999-03-19 2001-09-28 Use of stabilized oligonucleotides for preparing a medicament with antitumor activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9903433A FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral

Publications (2)

Publication Number Publication Date
FR2790955A1 FR2790955A1 (fr) 2000-09-22
FR2790955B1 true FR2790955B1 (fr) 2003-01-17

Family

ID=9543401

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9903433A Expired - Fee Related FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral

Country Status (12)

Country Link
US (2) US7700569B1 (https=)
EP (1) EP1162982B9 (https=)
JP (1) JP2002539265A (https=)
AT (1) ATE288759T1 (https=)
AU (1) AU3300600A (https=)
CA (1) CA2371990A1 (https=)
DE (1) DE60018050T2 (https=)
DK (1) DK1162982T3 (https=)
ES (1) ES2235839T3 (https=)
FR (1) FR2790955B1 (https=)
PT (1) PT1162982E (https=)
WO (1) WO2000056342A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
EP1675614A2 (en) * 2003-10-11 2006-07-05 Inex Pharmaceuticals Corp. Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
WO2006010838A2 (fr) * 2004-06-25 2006-02-02 Institut Gustave Roussy Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant
EP1649859A1 (fr) * 2004-10-22 2006-04-26 Institut Gustave Roussy Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
AU2006220835B2 (en) 2005-03-04 2012-01-19 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
CA2723672C (en) * 2007-05-11 2019-09-03 Adynxx, Inc. Gene expression and pain
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
US20130210896A1 (en) * 2011-11-09 2013-08-15 City Of Hope Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System
EP3511022A1 (en) 2012-05-10 2019-07-17 Adynxx, Inc. Formulations for the delivery of active ingredients
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
JP2021516957A (ja) 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
JP7625521B2 (ja) 2018-12-28 2025-02-03 トランスジーン ｍ２欠陥ポックスウイルス
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
JPH04352724A (ja) * 1990-07-27 1992-12-07 Mitsui Toatsu Chem Inc 免疫調節型治療剤
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
AU2580892A (en) 1991-09-05 1993-04-05 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
ATE235549T1 (de) 1993-04-30 2003-04-15 Biognostik Ges Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2
EP0708829B8 (en) * 1993-07-10 2004-07-21 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
EP1584682B1 (en) * 1993-09-20 2009-07-15 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
ATE509102T1 (de) * 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
EP0914324B1 (en) * 1996-05-22 2001-12-05 McGILL UNIVERSITY Specific inhibitors of dna methyltransferase enzyme
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US5965420A (en) * 1997-03-05 1999-10-12 Smithkline Beecham Corporation Human protein kinases hYAK3
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
ATE294388T1 (de) * 1997-08-29 2005-05-15 Univ California Modulatoren der cytosin-5-methyl-transferase und verfahren zu ihrer verwendung
DK1009413T3 (da) * 1997-09-05 2007-06-11 Univ California Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6060310A (en) 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
US6020475A (en) 1998-02-10 2000-02-01 Isis Pharmeuticals, Inc. Process for the synthesis of oligomeric compounds
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6166239A (en) 1998-09-04 2000-12-26 Isis Pharmaceuticals, Inc. Oligonucleotide protecting groups
WO2000016804A1 (en) 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
US6069243A (en) 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
EP1117433A1 (en) 1998-10-09 2001-07-25 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
AU4237300A (en) 1999-04-19 2000-11-02 Engelhard Corporation Catalyst composition comprising ceria and a platinum group metal
WO2001051061A1 (en) * 2000-01-14 2001-07-19 Intrabiotics Pharmaceuticals, Inc. Derivatives of polyene macrolides and preparation and use thereof

Also Published As

Publication number Publication date
ES2235839T3 (es) 2005-07-16
US7108844B2 (en) 2006-09-19
ATE288759T1 (de) 2005-02-15
FR2790955A1 (fr) 2000-09-22
WO2000056342A3 (fr) 2001-07-26
EP1162982B1 (fr) 2005-02-09
JP2002539265A (ja) 2002-11-19
CA2371990A1 (fr) 2000-09-28
DE60018050D1 (de) 2005-03-17
US20020192184A1 (en) 2002-12-19
DE60018050T2 (de) 2006-02-23
EP1162982B9 (fr) 2005-07-06
AU3300600A (en) 2000-10-09
PT1162982E (pt) 2005-05-31
US7700569B1 (en) 2010-04-20
DK1162982T3 (da) 2005-06-13
EP1162982A2 (fr) 2001-12-19
WO2000056342A2 (fr) 2000-09-28

Similar Documents

Publication Publication Date Title
FR2790955B1 (fr) Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
WO2001093841A3 (en) Barbituric acid analogs as therapeutic agents
MXPA03007712A (es) Sales farmaceuticas.
NO995819D0 (no) Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
MX9700885A (es) Nuevas heteroariloxazolidinonas.
IL190905A0 (en) 4-alkoxy cyclohexane-1-amino carboxylic acids and processes for their prepatation
ATE433989T1 (de) Pharmazeutisch wirksame uridinester
HU9501623D0 (en) Use of 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) as an antidepressant drug
PL369999A1 (en) 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivatives or salts thereof
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
IT1318667B1 (it) Medicamento antinfiammatorio.
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
IT1312569B1 (it) Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
EP1062948A4 (en) DRUGS AGAINST CARDIAC DIASTOLIC DISORDERS
ATE308984T1 (de) Arzneiformen zur behandlung von krankheiten, die auf aktivierung des ppar-gamma-rezeptors ansprechen
MXPA03009723A (es) Procedimientos e intermediarios para preparar epoxidos substituidos de bencilo.
ATE275551T1 (de) Halogenpyrimidine
DE50010009D1 (en) Hydroxamsäurederivate
ES2179668T3 (es) Un compuesto wf002, su produccion y su uso.
MXPA02002486A (es) Uso de dexrazoxano para tratar la psoriasis.
CA2353909A1 (en) Betacellulin muteins
WO2001041543A3 (en) Pesticidal activity of functionalized alkenes
NO903585D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksaziner.
Japsen Gebbie's departure is evidence of Clinton's AIDS policy problems.

Legal Events

Date Code Title Description
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 17

ST Notification of lapse

Effective date: 20161130